title: Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters.
abstract: OBJECTIVE
  The amorphous form of a drug may provide enhanced solubility, dissolution rate, and bioavailability but will also potentially crystallize over time. Miscible polymeric additives provide a means to increase physical stability. Understanding the miscibility of drug-polymer systems is of interest to optimize the formulation of such systems. The purpose of this work was to develop experimental models which allow for more quantitative estimates of the thermodynamics of mixing amorphous drugs with glassy polymers.
  
  
  METHODS
  The thermodynamics of mixing several amorphous drugs with amorphous polymers was estimated by coupling solution theory with experimental data. The entropy of mixing was estimated using Flory-Huggins lattice theory. The enthalpy of mixing and any deviations from the entropy as predicted by Flory-Huggins lattice theory were estimated using two separate experimental techniques; (1) melting point depression of the crystalline drug in the presence of the amorphous polymer was measured using differential scanning calorimetry and (2) determination of the solubility of the drug in 1-ethyl-2-pyrrolidone. The estimated activity coefficient was used to calculate the free energy of mixing of the drugs in the polymers and the corresponding solubility.
  
  
  RESULTS
  Mixtures previously reported as miscible showed various degrees of melting point depression while systems reported as immiscible or partially miscible showed little or no melting point depression. The solubility of several compounds in 1-ethyl-2-pyrrolidone predicts that most drugs have a rather low solubility in poly(vinylpyrrolidone).
  
  
  CONCLUSIONS
  Miscibility of various drugs with polymers can be explored by coupling solution theories with experimental data. These approximations provide insight into the physical stability of drug-polymer mixtures and the thermodynamic driving force for crystallization.
authors.affiliation: Materials Characterization and Technology Assessment, Merck & Co., Inc., West Point, Pennsylvania 19486, USA.
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Marsac
authors.forename: Tonglei
authors.initials: T
authors.lastname: Li
authors.forename: Lynne S
authors.initials: LS
authors.lastname: Taylor
mesh_terms: D002626:Chemistry, Pharmaceutical; D003460:Crystallization; D006860:Hydrogen Bonding; D008970:Molecular Weight; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry*; D012995:Solubility; D013696:Temperature; D013816:Thermodynamics
chemical_list: D004364:Pharmaceutical Preparations; D011108:Polymers
references.citation: Int J Pharm. 2002 Jan 14;231(2):131-44
references.pmid: 11755266
references.citation: Drug Dev Ind Pharm. 2002 May;28(5):473-93
references.pmid: 12098838
references.citation: Pharm Res. 2006 Oct;23(10):2306-16
references.pmid: 16927182
references.citation: J Pharm Sci. 1998 Jun;87(6):694-701
references.pmid: 9607945
references.citation: J Pharm Sci. 2000 Oct;89(10):1325-34
references.pmid: 10980507
references.citation: J Pharm Sci. 1998 Dec;87(12):1615-21
references.pmid: 10189276
references.citation: Adv Drug Deliv Rev. 2003 Apr 25;55(4):519-48
references.pmid: 12706049
references.citation: Eur J Pharm Biopharm. 2004 Sep;58(2):445-55
references.pmid: 15296966
references.citation: J Pharm Sci. 1999 Nov;88(11):1182-90
references.pmid: 10564068
references.citation: J Pharm Sci. 1995 Aug;84(8):983-6
references.pmid: 7500284
references.citation: Pharm Res. 2002 Apr;19(4):477-83
references.pmid: 12033383
references.citation: Ophthalmologica. 2001 May-Jun;215(3):143-55
references.pmid: 11340382
references.citation: Int Ophthalmol. 1994;18(1):1-4
references.pmid: 7960409
references.citation: Trans Ophthalmol Soc U K. 1976 Jul;96(2):319-21
references.pmid: 1070885
references.citation: Pharmacol Res. 2008 Mar;57(3):171-80
references.pmid: 18339557
references.citation: Invest Ophthalmol. 1970 Apr;9(4):250-5
references.pmid: 5435768
references.citation: J Cardiovasc Pharmacol. 2008 Feb;51(2):118-25
references.pmid: 18287878
references.citation: J Pharm Sci. 2007 Nov;96(11):2829-37
references.pmid: 17979210
references.citation: Expert Opin Drug Deliv. 2007 Jul;4(4):403-16
references.pmid: 17683253
references.citation: J Pharm Sci. 2006 Dec;95(12):2692-705
references.pmid: 16892209
references.citation: Pharm Res. 2003 Jul;20(7):1047-54
references.pmid: 12880291
references.citation: J Pharm Sci. 1999 Oct;88(10):1058-66
references.pmid: 10514356
references.citation: Crit Rev Ther Drug Carrier Syst. 1984;1(1):39-90
references.pmid: 6400195
references.citation: Eur J Pharm Sci. 2001 Jan;12(3):261-9
references.pmid: 11113645
references.citation: Nanomedicine (Lond). 2007 Aug;2(4):483-509
references.pmid: 17716133
references.citation: Drugs. 1990 Dec;40(6):880-902
references.pmid: 2127741
references.citation: Optom Vis Sci. 1993 Dec;70(12):1012-8
references.pmid: 8115123
references.citation: Drug Dev Ind Pharm. 2002 Aug;28(7):795-807
references.pmid: 12236065
references.citation: Curr Eye Res. 2005 Dec;30(12):1071-80
references.pmid: 16354620
references.citation: Vestn Oftalmol. 1986 May-Jun;102(3):14-7
references.pmid: 3727241
references.citation: J Pharm Sci. 2004 Mar;93(3):646-53
references.pmid: 14762903
references.citation: Pharm Res. 1994 Aug;11(8):1166-73
references.pmid: 7971719
references.citation: South Med J. 2008 Feb;101(2):174-8
references.pmid: 18364620
references.citation: Cardiology. 1991;79 Suppl 2:5-13
references.pmid: 1760830
references.citation: Tissue Eng. 2007 Oct;13(10):2369-85
references.pmid: 17658993
references.citation: Crit Rev Ther Drug Carrier Syst. 2003;20(2-3):215-47
references.pmid: 14584524
references.citation: J Pharm Sci. 2001 Dec;90(12):1991-2004
references.pmid: 11745758
references.citation: Pharm Acta Helv. 1986;61(3):69-88
references.pmid: 3520598
references.citation: Pharm Res. 1997 Dec;14(12):1691-8
references.pmid: 9453055
references.citation: J Biomed Mater Res. 1983 Jan;17(1):109-28
references.pmid: 6826569
references.citation: Pharm Res. 2000 Apr;17(4):397-404
references.pmid: 10870982
references.citation: Pharm Res. 2003 Sep;20(9):1417-22
references.pmid: 14567636
references.citation: Pharm Res. 2006 Oct;23(10):2417-26
references.pmid: 16933098